Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Klas Kärre(Karolinska Institutet), Rolf Kiessling(Unknown)
Cited by 2,140
Related Papers
Classification of current anticancer immunotherapies
|Oncotarget|2014|469
Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign
|Cancer Research|2010|377
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo
|Journal of Clinical Investigation|2009|331